Conceptual therapeutics for small cell lung cancer

---

Review Article

Author Details : Sunil Chaudhry*, Abhijit Trailokya

Volume : 9, Issue : 3, Year : 2024

Article Page : 98-103

https://doi.org/10.18231/j.ijirm.2024.020

Suggest article by email

Get Permission

---

Abstract

Small-cell lung cancer (SCLC) is 15% of all lung cancers and is definitely of the most aggressive tumors, with relative poor prognosis and with limited drugs. 90% of patients of SCLC are regular smokers providing the link that tobacco carcinogens are responsible for the initiation. The value of female smokers (79.9) is more than that of male smokers (20.3). The 5 year survival rate has been reported to be less than 7%. The cornerstone of treatment for any stage of SCLC is etoposide-platinum based chemotherapy; in limited stage (LS) along with concomitant radiotherapy to thorax and mediastinum. Novel drugs used in treatment of SCLC are: Atezolizumab. Everolimus, Durvalumab, Iplimumab, Tarlatamab which target PD-L1, a protein related to PD-1 that is found on some tumor cells and immune cells.The combination of thoracic RT with chemotherapy results in improved survival compared to chemotherapy alone.The role of surgery in SCLC has been under question, though performed in earlier stage 1 as per the International Guidelines. Some reports document better OS in early stage III too.
 

Keywords: Small cell lung cancer, TP53 mutations, Therapeutic targets : Chemotherapy, Immune­checkpoint inhibitors, Radiotherapy, Surgery

How to cite : Chaudhry S, Trailokya A, Conceptual therapeutics for small cell lung cancer. IP Indian J Immunol Respir Med 2024;9(3):98-103

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.